Aeolus Pharmaceuticals, Inc.
AOLS · OTC
9/30/2016 | 9/30/2015 | 9/30/2014 | 9/30/2013 | |
|---|---|---|---|---|
| Revenue | $2,076 | $3,111 | $9,631 | $3,928 |
| % Growth | -33.3% | -67.7% | 145.2% | – |
| Cost of Goods Sold | $2,881 | $3,509 | $6,966 | $3,360 |
| Gross Profit | -$805 | -$398 | $2,665 | $568 |
| % Margin | -38.8% | -12.8% | 27.7% | 14.5% |
| R&D Expenses | $2,881 | $3,509 | $6,966 | $3,360 |
| G&A Expenses | $2,468 | $2,228 | $2,703 | $3,266 |
| SG&A Expenses | $2,468 | $2,228 | $2,745 | $3,266 |
| Sales & Mktg Exp. | $0 | $0 | $42 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,349 | $5,737 | $9,711 | $3,266 |
| Operating Income | -$3,273 | -$2,626 | -$80 | -$2,698 |
| % Margin | -157.7% | -84.4% | -0.8% | -68.7% |
| Other Income/Exp. Net | -$285 | -$2 | $0 | -$510 |
| Pre-Tax Income | -$3,558 | -$2,628 | -$80 | -$3,208 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3,558 | -$2,628 | -$80 | -$3,208 |
| % Margin | -171.4% | -84.5% | -0.8% | -81.7% |
| EPS | -0.04 | -0.02 | -0.001 | -0.03 |
| % Growth | -100% | -3,233.3% | 98% | – |
| EPS Diluted | -0.04 | -0.02 | -0.001 | -0.03 |
| Weighted Avg Shares Out | 148,668 | 135,883 | 134,667 | 106,554 |
| Weighted Avg Shares Out Dil | 148,668 | 135,883 | 134,667 | 106,554 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $285 | $2 | $0 | $0 |
| Depreciation & Amortization | $3,273 | $2,626 | $6 | $6 |
| EBITDA | -$3,273 | -$2,626 | -$80 | -$2,692 |
| % Margin | -157.7% | -84.4% | -0.8% | -68.5% |